Literature DB >> 18326939

HDACs and HDAC inhibitors in colon cancer.

John M Mariadason1.   

Abstract

The histone deacetylase (HDAC) family of transcriptional co-repressors have emerged as important regulators of colon cell maturation and transformation. Pharmacological inhibitors of class I and II HDAC activity (HDACi) are potent inducers of growth arrest, differentiation and apoptosis of colon cancer cells in vitro and in vivo, implicating a role for these HDACs in tumor promotion. Consistent with this role, expression of several HDACs are upregulated in colon tumors, while downregulation of specific HDACs inhibits growth of colon cancer cells in vitro and intestinal tumorigenesis in vivo. This review focuses on the function and transcriptional mechanisms by which class I and II HDACs regulate colon cell maturation and transformation, and on the mechanisms by which HDACi induce growth arrest, differentiation and apoptosis of colon cancer cells. The emerging role of the class III HDAC, Sirt1, in colon cancer progression is also discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326939     DOI: 10.4161/epi.3.1.5736

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  87 in total

1.  Regulation of CRADD-caspase 2 cascade by histone deacetylase 1 in gastric cancer.

Authors:  Qi Shen; Wanfen Tang; Jie Sun; Lifeng Feng; Hongchuan Jin; Xian Wang
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?

Authors:  Sun Il Lee; Xiangsheng Zuo; Imad Shureiqi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Polycomb repressive complex 2 impedes intestinal cell terminal differentiation.

Authors:  Yannick D Benoit; Manon B Lepage; Taoufik Khalfaoui; Eric Tremblay; Nuria Basora; Julie C Carrier; Lorraine J Gudas; Jean-François Beaulieu
Journal:  J Cell Sci       Date:  2012-03-30       Impact factor: 5.285

4.  HDAC1, a novel marker for benign teratomas.

Authors:  Elisabeth Simboeck; Luciano Di Croce
Journal:  EMBO J       Date:  2010-12-01       Impact factor: 11.598

Review 5.  Epigenetics and autosomal dominant polycystic kidney disease.

Authors:  Xiaogang Li
Journal:  Biochim Biophys Acta       Date:  2010-10-20

6.  ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types.

Authors:  Anderly C Chüeh; Janson W T Tse; Michael Dickinson; Paul Ioannidis; Laura Jenkins; Lars Togel; BeeShin Tan; Ian Luk; Mercedes Davalos-Salas; Rebecca Nightingale; Matthew R Thompson; Bryan R G Williams; Guillaume Lessene; Erinna F Lee; Walter D Fairlie; Amardeep S Dhillon; John M Mariadason
Journal:  Clin Cancer Res       Date:  2017-06-13       Impact factor: 12.531

7.  Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.

Authors:  Huilai Zhang; Huijuan Lv; Xiaohui Jia; Ge Hu; Lingzhe Kong; Tingting Zhang; Linyu Li; Yi Pan; Qiongli Zhai; Bin Meng; Xi Wang; Huaqing Wang; Xianhuo Wang
Journal:  Oncol Lett       Date:  2019-05-30       Impact factor: 2.967

8.  Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.

Authors:  Shuai Gao; Jie Zang; Qianwen Gao; Xuewu Liang; Qinge Ding; Xiaoyang Li; Wenfang Xu; C James Chou; Yingjie Zhang
Journal:  Bioorg Med Chem       Date:  2017-03-19       Impact factor: 3.641

9.  Making sense of HDAC2 mutations in colon cancer.

Authors:  John M Mariadason
Journal:  Gastroenterology       Date:  2008-10-11       Impact factor: 22.682

10.  Site-specific acetylation of the proteasome activator REGγ directs its heptameric structure and functions.

Authors:  Jiang Liu; Ying Wang; Lei Li; Li Zhou; Haibin Wei; Qingxia Zhou; Jian Liu; Weicang Wang; Lei Ji; Peipei Shan; Yan Wang; Yuanyuan Yang; Sung Yun Jung; Pei Zhang; Chuangui Wang; Weiwen Long; Bianhong Zhang; Xiaotao Li
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.